Inmune Bio (INMB) Return on Capital Employed (2019 - 2025)
Inmune Bio (INMB) has disclosed Return on Capital Employed for 7 consecutive years, with 1.94% as the latest value for Q4 2025.
- Quarterly Return on Capital Employed fell 84.0% to 1.94% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.94% through Dec 2025, down 84.0% year-over-year, with the annual reading at 1.72% for FY2025, 68.0% down from the prior year.
- Return on Capital Employed hit 1.94% in Q4 2025 for Inmune Bio, down from 1.82% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 0.29% in Q1 2021 to a low of 1.94% in Q4 2025.
- Historically, Return on Capital Employed has averaged 0.8% across 5 years, with a median of 0.48% in 2023.
- Biggest five-year swings in Return on Capital Employed: rose 9bps in 2021 and later tumbled -84bps in 2025.
- Year by year, Return on Capital Employed stood at 0.29% in 2021, then fell by -23bps to 0.36% in 2022, then tumbled by -99bps to 0.72% in 2023, then tumbled by -52bps to 1.09% in 2024, then crashed by -77bps to 1.94% in 2025.
- Business Quant data shows Return on Capital Employed for INMB at 1.94% in Q4 2025, 1.82% in Q3 2025, and 1.93% in Q2 2025.